Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema)1.0 mg/1.0 mg s.c. once weekly versus tirzepatide

Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema)1.0 mg/1.0 mg s.c. once weekly versus tirzepatide 5 mg s.c. once weekly in participants with type 2diabetes inadequately controlled on metformin, SGLT2 inhibitor or both

Abierta

Código protocolo: NN9388-7741
Código EudraCT: No aplica
Grupo de investigación: Diabetes y Metabolismo
Servicio: Endocrinología
Investigador/a principal: Ciudin Mihai, Andreea
Patología: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
Fase: Fase III